Ensayo clínico NCT07063745 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Ensayo clínico NCT07063745 (fase II/III) figura como «en reclutamiento» en ClinicalTrials.gov.

Patología: Metastatic Non-small Cell Lung Cancer With MTAP Deletion · Intervenciones registradas: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel · Fechas registradas (fuente): 2026-01-02, 2031-08-12, 2025-07-14, 2026-10-23.

Resumen del estudio (fuente: ClinicalTrials.gov, texto original en inglés):

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Fuente: https://clinicaltrials.gov/study/NCT07063745